Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The COVID-19 pandemic has seen some extraordinary medical feats and achievements, which are being rightly celebrated. Researchers at Oxford University have been at the forefront of global efforts, including the first human trials of a COVID-19 vaccine, and the world’s biggest trial of potential COVID-19 treatments, RECOVERY. 

The Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial has recruited more than 10,000 patients in 176 hospitals in just two months - truly incredible figures for that timescale, making it the fastest ever recruiting individually randomised controlled trial. From conception to launch took just nine days! The trial is being co-led by Professor Peter Horby (Nuffield Department of Medicine) and Professor Martin Landray (Nuffield Department of Population Health), and is testing existing drugs, all with well-known side effects and confirmed safety, on hospital inpatients with suspected or confirmed COVID-19. 

Each participant is randomised via a secure 24/7 web-based system. Participants receive either the usual standard of hospital care, or one of four drugs - lopinavir-ritonavir, normally used to treat HIV, the steroid dexamethasone (or alternative corticosteroids), used in a wide range of conditions to reduce inflammation, hydroxychloroquine, which is mainly used as an anti-malarial drug and the antibiotic azithromycin. The study allows a second randomisation for patients with progressive COVID-19, who receive the usual standard of care or tocilizumab, an immunosuppressive drug. The researchers will be able to fairly compare each of the treatments with usual standard of care and work out which, if any, make a difference. The trial design is flexible and as new treatments are suggested or become available, it can be adapted to accommodate them. Indeed, azithromycin, tocilizumab and most recently, convalescent plasma (CP) arms were added after the trial began recruitment; CP is about to be offered on top of the main first line randomisation options. 

Read more on the Nuffield Department of Population Health website

Similar stories

Oxford University academics recognised in Queen’s Birthday Honours

The pioneering work of members of the University, including research into tackling the Coronavirus pandemic, has been recognised in The Queen's Birthday Honours List.

Two Oxford Professors elected as EMBO Members

Professor Robert Klose and Professor Ervin Fodor are two of 64 life scientists to be elected to The European Molecular Biology Organization (EMBO).

Scientists make DNA breakthrough which could identify why some people are more affected by Covid-19

Scientists from the MRC Weatherall Institute of Molecular Medicine at Oxford University have developed a method that allows them to see, with far greater accuracy, how DNA forms large scale structures within a cell nucleus.

AI endoscopy enables 3D surface measurements of pre-cancerous condition in oesophagus

Clinicians and engineers in Oxford have begun using artificial intelligence alongside endoscopy to get more accurate readings of the pre-cancerous condition Barrett’s oesophagus and so determine patients most at risk of developing cancer.

The COVID-19 International Modelling Consortium (CoMo Consortium) enters a new phase

Created in March 2020 to assist policymakers to make use of existing evidence in mathematical and epidemiological models to inform strategies for minimising the impact of COVID-19, the CoMo Consortium brings together mathematical modellers, epidemiologists, health economists and public health experts from more than 40 countries across Africa, Asia and South and North America.

New Head of the Department of Psychiatry – Professor Belinda Lennox

Professor Belinda Lennox has been welcomed to the role of Head of the Department of Psychiatry at the University of Oxford and will take over leadership in October 2021.